Transient, low levels of antipalivizumab antibody were observed in one child after the second dose of palivizumab that dropped to undetectable levels at the fifth and seventh dose.
Se detectaron niveles bajos transitorios de anticuerpos antipalivizumab en un niño después de la segunda dosis de palivizumab, que descendieron a niveles indetectables a la quinta y séptima dosis.